Neurocrine Clinical Site

Oklahoma City, Oklahoma 73120

1 studies enrolling now · 13 studies all time

What they study most

Anhedonia, Bipolar Disorder, Cerebral Palsy, Congenital Adrenal Hyperplasia, Dyskinesia, Major Depressive Disorder, Schizoaffective Disorder, Schizophrenia, Tardive Dyskinesia, Tardive Dyskinesia (TD), Tourette Syndrome

Studies at this site

• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy — Completed
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia — Completed
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia — Completed
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) — Running, not enrolling
• Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) — Completed
• Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD — Completed
• Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome — Stopped early
• Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia — Completed
• The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine — Completed
• Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents — Status unconfirmed